A Phase I PET study showed Intra-Cellular Therapies' experimental antipsychotic drug ITI-007 interacted with key targets in the living human brain, a mechanism that will influence drug action. "We believe that these results will translate into a reduced need to impose high doses of drugs on patients suffering from schizophrenia and other disorders," CEO Sharon Mates said.

Full Story:
PR Newswire

Related Summaries